Global Lip Augmentation Market Poised to Double by 2035 Amid Rising Demand

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Global lip augmentation market expected to double from $7.91B (2025) to $17.37B (2035), driven by social media influence, improved technology, and increased mainstream acceptance.

Global Lip Augmentation Market Poised to Double by 2035 Amid Rising Demand

The global lip augmentation market is expected to expand significantly over the next decade, growing from USD 7.91 billion in 2025 to USD 17.37 billion by 2035, according to market analysis. This expansion represents a compound annual growth rate (CAGR) of 8.21%, reflecting sustained demand for cosmetic enhancement procedures across international markets.

Several factors are contributing to this market trajectory. Social media platforms have amplified beauty trend cycles and consumer interest in cosmetic procedures, while technological innovations in dermal filler formulations have improved safety profiles and results. Additionally, cosmetic procedures have achieved greater mainstream acceptance across broader demographic groups, reducing previous social stigma and expanding the potential customer base.

Dermal fillers maintain dominant market positioning, accounting for 69.69% of the total market share. Within the filler category, hyaluronic acid-based products lead with 74.55% market penetration, reflecting their established efficacy and widespread clinical adoption. These product categories are expected to remain central to market growth throughout the forecast period.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 16

Related Coverage

The Motley Fool

Two Dividend Aristocrats Offer Reliable Income Streams Amid Market Volatility

AbbVie and Realty Income offer reliable dividend income with 54 and 31 consecutive years of increases respectively, yielding 3.27% and 5.09%.

ABBVOABT
The Motley Fool

Three High-Yield Stocks Deliver Monthly Dividend Income for Patient Investors

Three dividend stocks—AbbVie (3.3%), Medtronic (3.6%), and Enbridge (5.2%)—create monthly income through staggered payments. Combined strategy offers consistent cash flow from financially strong healthcare and energy companies.

ABBVMDTENB
The Motley Fool

AbbVie Crushes Q1 Forecasts as Immunology Powerhouses Accelerate Growth Trajectory

AbbVie beats Q1 earnings with $15B revenue, accelerates $31B immunology drug guidance to 2026 from 2027. Stock down 10% YTD despite outperformance.

ABBV
The Motley Fool

Three Dividend Powerhouses Offer Investors Stable Income at Attractive Valuations

AbbVie, Verizon, and Canadian Natural Resources offer compelling dividend yields (3.4%-5.9%) with growth potential at low valuations heading into May 2026.

ABBVVZCNQ
GlobeNewswire Inc.

Nxera Pharma Posts Strong Q1 2026 as Spinoff Centessa Fetches $7.8B Lilly Deal

Nxera Pharma reported JPY 11.3B Q1 revenue driven by R&D milestones. Spinoff Centessa agreed to $7.8B acquisition by Eli Lilly.

ABBVLLYCNTA
GlobeNewswire Inc.

AbbVie Backs Montreal Biotech RIME Therapeutics with Innovation Prize Package

AbbVie and adMare BioInnovations award RIME Therapeutics the AbbVie Biotech Innovators Prize, providing lab space, equipment, and executive mentorship.

ABBV